Evidence map›Paper›PMID 37325452›Full record

ReviewHeliyon2023

Multidimensional futuristic approaches to address the pandemics beyond COVID-19.

Shifa Bushra Kotwal, Nidhi Orekondey, Gargi Prasad Saradadevi, Neha Priyadarshini, Navinchandra V Puppala, Mahak Bhushan, Snehasri Motamarry, Rahul Kumar, Gireesha Mohannath, Ruchi Jain Dey

Abstract readReview
In one paragraph

Review in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shifa Bushra KotwalDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.
Nidhi OrekondeyDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.
Gargi Prasad SaradadeviDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.
Neha PriyadarshiniDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.
Navinchandra V PuppalaDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.
Mahak BhushanDepartment of Biological Sciences, Indian Institute of Science Education and Research (IISER), Kolkata, West Bengal 741246, India.
Snehasri MotamarryDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.
Rahul KumarDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.
Gireesha MohannathDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.
Ruchi Jain DeyDepartment of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana 500078, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, the impact of the coronavirus disease 2019 (COVID-19) pandemic has been enormous and unrelenting with ∼6.9 million deaths and ∼765 million infections. This review mainly focuses on the recent advances and potentially novel molecular tools for viral diagnostics and therapeutics with far-reaching implications in managing the future pandemics. In addition to briefly highlighting the existing and recent methods of viral diagnostics, we propose a couple of potentially novel non-PCR-based methods for rapid, cost-effective, and single-step detection of nucleic acids of viruses using RNA mimics of green fluorescent protein (GFP) and nuclease-based approaches. We also highlight key innovations in miniaturized Lab-on-Chip (LoC) devices, which in combination with cyber-physical systems, could serve as ideal futuristic platforms for viral diagnosis and disease management. We also discuss underexplored and underutilized antiviral strategies, including ribozyme-mediated RNA-cleaving tools for targeting viral RNA, and recent advances in plant-based platforms for rapid, low-cost, and large-scale production and oral delivery of antiviral agents/vaccines. Lastly, we propose repurposing of the existing vaccines for newer applications with a major emphasis on Bacillus Calmette-Guérin (BCG)-based vaccine engineering.

Indexed as

BCGCOVID-19DiagnosticsLab-on-ChipRibozymeRNA mimics Of GFPRPASARS-CoV-2TherapeuticsVaccines

Identifiers

PMID37325452
PMCPMC10257889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.